A bold new chapter is unfolding in the fight against one of the most complex forms of cancer—head and neck cancer that resists PD-1 inhibitors. For years, PD-1 blockade therapies offered new hope to patients by enhancing immune responses. But as resistance to these therapies becomes more common, researchers and biotech firms are intensifying their efforts to outsmart the cancer’s...